EGFR-IN-1;EGFR IN 1,EGFRIN1;2-Propenamide, N-[3-[2-[[4-[2-(dimethylamino)ethoxy]-2-methoxyphenyl]amino]-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl]phenyl]-
EGFR-IN-1 is an orally active, irreversible mutant-selective EGFR inhibitor targeting L858R/T790M mutations; it exhibits 100-fold greater inhibitory activity against gefitinib-resistant EGFR L858R/T790M compared to wild-type EGFR; demonstrates potent antiproliferative activity against H1975 and HCC827 cells; and possesses antitumor activity.